Status:
ACTIVE_NOT_RECRUITING
Flu Vaccine Responses in the Setting of Melanoma Treatment
Lead Sponsor:
University of Pennsylvania
Conditions:
Viral Vaccines
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Influenza vaccination is indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. We are conducting a prospective unblinded study of influenza vaccine r...
Detailed Description
Influenza vaccination is indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. In particular, immune responses following influenza vaccination have n...
Eligibility Criteria
Inclusion
- adults capable of providing consent
- have a diagnosis of locally advanced or metastatic melanoma
Exclusion
- are allergic to influenza vaccination
- have received influenza vaccination within the past 6 months
- require prednisone, methotrexate, or other immunosuppressing medications
- have HIV infection
- have a history of solid organ or bone marrow transplant
- require combination immunotherapy
- are on other studies requiring blood draws that might exceed 450 mL total during the period of the influenza vaccine study
Key Trial Info
Start Date :
October 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03315975
Start Date
October 20 2017
End Date
July 1 2026
Last Update
August 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104